Copyright Reports & Markets. All rights reserved.

Global Angina Pectoris Drugs Market Insights, Forecast to 2025

Request for Sample of this report
Buy now

Table of Contents

    1 Study Coverage

    • 1.1 Angina Pectoris Drugs Product
    • 1.2 Market Segments
    • 1.3 Key Manufacturers Covered
    • 1.4 Market by Type
      • 1.4.1 Global Angina Pectoris Drugs Market Size Growth Rate by Product
      • 1.4.2 Beta Blockers
      • 1.4.3 Calcium Antagonists
      • 1.4.4 Anticoagulants
      • 1.4.5 Anti-Platelets
      • 1.4.6 Others
    • 1.5 Market by End User
      • 1.5.1 Global Angina Pectoris Drugs Market Size Growth Rate by End User
      • 1.5.2 Hospitals
      • 1.5.3 Clinics
      • 1.5.4 ASCs
    • 1.6 Study Objectives
    • 1.7 Years Considered

    2 Executive Summary

    • 2.1 Global Angina Pectoris Drugs Market Size
      • 2.1.1 Global Angina Pectoris Drugs Revenue 2014-2025
      • 2.1.2 Global Angina Pectoris Drugs Sales 2014-2025
    • 2.2 Angina Pectoris Drugs Growth Rate by Regions
      • 2.2.1 Global Angina Pectoris Drugs Sales by Regions
      • 2.2.2 Global Angina Pectoris Drugs Revenue by Regions

    3 Breakdown Data by Manufacturers

    • 3.1 Angina Pectoris Drugs Sales by Manufacturers
      • 3.1.1 Angina Pectoris Drugs Sales by Manufacturers
      • 3.1.2 Angina Pectoris Drugs Sales Market Share by Manufacturers
      • 3.1.3 Global Angina Pectoris Drugs Market Concentration Ratio (CR5 and HHI)
    • 3.2 Angina Pectoris Drugs Revenue by Manufacturers
      • 3.2.1 Angina Pectoris Drugs Revenue by Manufacturers (2014-2019)
      • 3.2.2 Angina Pectoris Drugs Revenue Share by Manufacturers (2014-2019)
    • 3.3 Angina Pectoris Drugs Price by Manufacturers
    • 3.4 Angina Pectoris Drugs Manufacturing Base Distribution, Product Types
      • 3.4.1 Angina Pectoris Drugs Manufacturers Manufacturing Base Distribution, Headquarters
      • 3.4.2 Manufacturers Angina Pectoris Drugs Product Type
      • 3.4.3 Date of International Manufacturers Enter into Angina Pectoris Drugs Market
    • 3.5 Manufacturers Mergers & Acquisitions, Expansion Plans

    4 Breakdown Data by Product

    • 4.1 Global Angina Pectoris Drugs Sales by Product
    • 4.2 Global Angina Pectoris Drugs Revenue by Product
    • 4.3 Angina Pectoris Drugs Price by Product

    5 Breakdown Data by End User

    • 5.1 Overview
    • 5.2 Global Angina Pectoris Drugs Breakdown Data by End User

    6 North America

    • 6.1 North America Angina Pectoris Drugs by Countries
      • 6.1.1 North America Angina Pectoris Drugs Sales by Countries
      • 6.1.2 North America Angina Pectoris Drugs Revenue by Countries
      • 6.1.3 United States
      • 6.1.4 Canada
      • 6.1.5 Mexico
    • 6.2 North America Angina Pectoris Drugs by Product
    • 6.3 North America Angina Pectoris Drugs by End User

    7 Europe

    • 7.1 Europe Angina Pectoris Drugs by Countries
      • 7.1.1 Europe Angina Pectoris Drugs Sales by Countries
      • 7.1.2 Europe Angina Pectoris Drugs Revenue by Countries
      • 7.1.3 Germany
      • 7.1.4 France
      • 7.1.5 UK
      • 7.1.6 Italy
      • 7.1.7 Russia
    • 7.2 Europe Angina Pectoris Drugs by Product
    • 7.3 Europe Angina Pectoris Drugs by End User

    8 Asia Pacific

    • 8.1 Asia Pacific Angina Pectoris Drugs by Countries
      • 8.1.1 Asia Pacific Angina Pectoris Drugs Sales by Countries
      • 8.1.2 Asia Pacific Angina Pectoris Drugs Revenue by Countries
      • 8.1.3 China
      • 8.1.4 Japan
      • 8.1.5 Korea
      • 8.1.6 India
      • 8.1.7 Australia
      • 8.1.8 Indonesia
      • 8.1.9 Malaysia
      • 8.1.10 Philippines
      • 8.1.11 Thailand
      • 8.1.12 Vietnam
      • 8.1.13 Singapore
    • 8.2 Asia Pacific Angina Pectoris Drugs by Product
    • 8.3 Asia Pacific Angina Pectoris Drugs by End User

    9 Central & South America

    • 9.1 Central & South America Angina Pectoris Drugs by Countries
      • 9.1.1 Central & South America Angina Pectoris Drugs Sales by Countries
      • 9.1.2 Central & South America Angina Pectoris Drugs Revenue by Countries
      • 9.1.3 Brazil
    • 9.2 Central & South America Angina Pectoris Drugs by Product
    • 9.3 Central & South America Angina Pectoris Drugs by End User

    10 Middle East and Africa

    • 10.1 Middle East and Africa Angina Pectoris Drugs by Countries
      • 10.1.1 Middle East and Africa Angina Pectoris Drugs Sales by Countries
      • 10.1.2 Middle East and Africa Angina Pectoris Drugs Revenue by Countries
      • 10.1.3 GCC Countries
      • 10.1.4 Turkey
      • 10.1.5 Egypt
      • 10.1.6 South Africa
    • 10.2 Middle East and Africa Angina Pectoris Drugs by Product
    • 10.3 Middle East and Africa Angina Pectoris Drugs by End User

    11 Company Profiles

    • 11.1 Pfizer
      • 11.1.1 Pfizer Company Details
      • 11.1.2 Company Business Overview
      • 11.1.3 Pfizer Angina Pectoris Drugs Sales, Revenue and Gross Margin (2014-2019)
      • 11.1.4 Pfizer Angina Pectoris Drugs Products Offered
      • 11.1.5 Pfizer Recent Development
    • 11.2 Bayer
      • 11.2.1 Bayer Company Details
      • 11.2.2 Company Business Overview
      • 11.2.3 Bayer Angina Pectoris Drugs Sales, Revenue and Gross Margin (2014-2019)
      • 11.2.4 Bayer Angina Pectoris Drugs Products Offered
      • 11.2.5 Bayer Recent Development
    • 11.3 AstraZeneca
      • 11.3.1 AstraZeneca Company Details
      • 11.3.2 Company Business Overview
      • 11.3.3 AstraZeneca Angina Pectoris Drugs Sales, Revenue and Gross Margin (2014-2019)
      • 11.3.4 AstraZeneca Angina Pectoris Drugs Products Offered
      • 11.3.5 AstraZeneca Recent Development
    • 11.4 Gilead
      • 11.4.1 Gilead Company Details
      • 11.4.2 Company Business Overview
      • 11.4.3 Gilead Angina Pectoris Drugs Sales, Revenue and Gross Margin (2014-2019)
      • 11.4.4 Gilead Angina Pectoris Drugs Products Offered
      • 11.4.5 Gilead Recent Development
    • 11.5 Novartis
      • 11.5.1 Novartis Company Details
      • 11.5.2 Company Business Overview
      • 11.5.3 Novartis Angina Pectoris Drugs Sales, Revenue and Gross Margin (2014-2019)
      • 11.5.4 Novartis Angina Pectoris Drugs Products Offered
      • 11.5.5 Novartis Recent Development
    • 11.6 GlaxoSmithKline
      • 11.6.1 GlaxoSmithKline Company Details
      • 11.6.2 Company Business Overview
      • 11.6.3 GlaxoSmithKline Angina Pectoris Drugs Sales, Revenue and Gross Margin (2014-2019)
      • 11.6.4 GlaxoSmithKline Angina Pectoris Drugs Products Offered
      • 11.6.5 GlaxoSmithKline Recent Development
    • 11.7 Merck
      • 11.7.1 Merck Company Details
      • 11.7.2 Company Business Overview
      • 11.7.3 Merck Angina Pectoris Drugs Sales, Revenue and Gross Margin (2014-2019)
      • 11.7.4 Merck Angina Pectoris Drugs Products Offered
      • 11.7.5 Merck Recent Development
    • 11.8 Mylan
      • 11.8.1 Mylan Company Details
      • 11.8.2 Company Business Overview
      • 11.8.3 Mylan Angina Pectoris Drugs Sales, Revenue and Gross Margin (2014-2019)
      • 11.8.4 Mylan Angina Pectoris Drugs Products Offered
      • 11.8.5 Mylan Recent Development
    • 11.9 Teva Pharmaceutical
      • 11.9.1 Teva Pharmaceutical Company Details
      • 11.9.2 Company Business Overview
      • 11.9.3 Teva Pharmaceutical Angina Pectoris Drugs Sales, Revenue and Gross Margin (2014-2019)
      • 11.9.4 Teva Pharmaceutical Angina Pectoris Drugs Products Offered
      • 11.9.5 Teva Pharmaceutical Recent Development

    12 Future Forecast

    • 12.1 Angina Pectoris Drugs Market Forecast by Regions
      • 12.1.1 Global Angina Pectoris Drugs Sales Forecast by Regions 2019-2025
      • 12.1.2 Global Angina Pectoris Drugs Revenue Forecast by Regions 2019-2025
    • 12.2 Angina Pectoris Drugs Market Forecast by Product
      • 12.2.1 Global Angina Pectoris Drugs Sales Forecast by Product 2019-2025
      • 12.2.2 Global Angina Pectoris Drugs Revenue Forecast by Product 2019-2025
    • 12.3 Angina Pectoris Drugs Market Forecast by End User
    • 12.4 North America Angina Pectoris Drugs Forecast
    • 12.5 Europe Angina Pectoris Drugs Forecast
    • 12.6 Asia Pacific Angina Pectoris Drugs Forecast
    • 12.7 Central & South America Angina Pectoris Drugs Forecast
    • 12.8 Middle East and Africa Angina Pectoris Drugs Forecast

    13 Market Opportunities, Challenges, Risks and Influences Factors Analysis

    • 13.1 Market Opportunities and Drivers
    • 13.2 Market Challenges
    • 13.3 Market Risks/Restraints
    • 13.4 Macroscopic Indicators

    14 Value Chain and Sales Channels Analysis

    • 14.1 Value Chain Analysis
    • 14.2 Angina Pectoris Drugs Customers
    • 14.3 Sales Channels Analysis
      • 14.3.1 Sales Channels
      • 14.3.2 Distributors

    15 Research Findings and Conclusion

      16 Appendix

      • 16.1 Research Methodology
        • 16.1.1 Methodology/Research Approach
        • 16.1.2 Data Source
      • 16.2 Author Details

      Angina pectoris is a clinical indication characterized by precordial heaviness or discomfort due to transient myocardial ischemia without infarction, elicited by physical exertion or psychological stress. Angina pectoris is categorized as - stable, unstable, microvascular and Prinzmetal / variant. Angina pectoris is an initial presentation of coronary heart disease (CHD) and exerts a major impact on quality of life (QOL), costs to the society and ability to work.
      Chronic stable angina pectoris has a prevalence of 2.0 - 4.0% in the seven major markets (U.S., U.K., Germany, France, Italy, Spain, Japan). Heart Disease and Stroke Statistics from American Heart Association estimates indicate that over nine million adults in the U.S. have chronic angina pectoris.
      The global Angina Pectoris Drugs market is valued at xx million US$ in 2018 and will reach xx million US$ by the end of 2025, growing at a CAGR of xx% during 2019-2025. The objectives of this study are to define, segment, and project the size of the Angina Pectoris Drugs market based on company, product type, end user and key regions.

      This report studies the global market size of Angina Pectoris Drugs in key regions like North America, Europe, Asia Pacific, Central & South America and Middle East & Africa, focuses on the consumption of Angina Pectoris Drugs in these regions.
      This research report categorizes the global Angina Pectoris Drugs market by top players/brands, region, type and end user. This report also studies the global Angina Pectoris Drugs market status, competition landscape, market share, growth rate, future trends, market drivers, opportunities and challenges, sales channels and distributors.

      The following manufacturers are covered in this report, with sales, revenue, market share for each company:
      Pfizer
      Bayer
      AstraZeneca
      Gilead
      Novartis
      GlaxoSmithKline
      Merck
      Mylan
      Teva Pharmaceutical

      Market size by Product
      Beta Blockers
      Calcium Antagonists
      Anticoagulants
      Anti-Platelets
      Others
      Market size by End User
      Hospitals
      Clinics
      ASCs

      Market size by Region
      North America
      United States
      Canada
      Mexico
      Asia-Pacific
      China
      India
      Japan
      South Korea
      Australia
      Indonesia
      Singapore
      Malaysia
      Philippines
      Thailand
      Vietnam
      Europe
      Germany
      France
      UK
      Italy
      Spain
      Russia
      Central & South America
      Brazil
      Rest of Central & South America
      Middle East & Africa
      GCC Countries
      Turkey
      Egypt
      South Africa

      The study objectives of this report are:
      To study and analyze the global Angina Pectoris Drugs market size (value & volume) by company, key regions, products and end user, breakdown data from 2014 to 2018, and forecast to 2025.
      To understand the structure of Angina Pectoris Drugs market by identifying its various subsegments.
      To share detailed information about the key factors influencing the growth of the market (growth potential, opportunities, drivers, industry-specific challenges and risks).
      Focuses on the key global Angina Pectoris Drugs companies, to define, describe and analyze the sales volume, value, market share, market competition landscape and recent development.
      To project the value and sales volume of Angina Pectoris Drugs submarkets, with respect to key regions.
      To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

      In this study, the years considered to estimate the market size of Angina Pectoris Drugs are as follows:
      History Year: 2014-2018
      Base Year: 2018
      Estimated Year: 2019
      Forecast Year 2019 to 2025

      This report includes the estimation of market size for value (million US$) and volume (K Units). Both top-down and bottom-up approaches have been used to estimate and validate the market size of Angina Pectoris Drugs market, to estimate the size of various other dependent submarkets in the overall market. Key players in the market have been identified through secondary research, and their market shares have been determined through primary and secondary research. All percentage shares, splits, and breakdowns have been determined using secondary sources and verified primary sources.

      For the data information by region, company, type and application, 2018 is considered as the base year. Whenever data information was unavailable for the base year, the prior year has been considered.

      Buy now